ASRM Ethics and Practice Committees Release New Report Concluding Polygenic Embryo Screening Is Not Ready for Clinical Use
New analysis finds that PGT-P lacks proven clinical utility and raises significant scientific and ethical concerns
For Immediate Release
Washington, DC—Fertility and Sterility, the flagship publication of the American Society for Reproductive Medicine (ASRM), has published a joint report from the Ethics and Practice Committees evaluating the use of preimplantation genetic testing for polygenic disorders, known as PGT-P. The report concludes that this emerging technology is not ready for clinical practice and should not be offered as a reproductive service at this time, given the predictive uncertainties of the results and the substantial ethical considerations that it raises.
PGT-P aims to estimate an embryo’s potential risk for developing certain multifactorial diseases such as hypertension, heart disease and diabetes, but current predictive models are limited by insufficient data, incomplete understanding of gene and environment interactions, and a lack of diverse genomic representation. These gaps mean that the scores produced may not translate into meaningful clinical guidance for patients or providers. The Committees also note that whether individuals will ultimately develop the conditions for which PGT-P is being offered can be significantly impacted by factors such as diet, lifestyle and future medical treatments, with polygenic risk scoring accounting for only a small percentage of clinical variation.
Key Findings:
- PGT-P is a nascent and unproven technology that should not be used clinically at this time.
- Current evidence does not support the predictive accuracy, safety, or clinical value of polygenic embryo screening.
- The technology risks misleading patients by overstating what polygenic risk scores can reliably determine.
- PGT-P raises significant ethical issues, including concerns about equity, autonomy, disease prioritization, and the potential for biased or incomplete risk assessments.
- Any use of PGT-P should occur only in research settings under Institutional Review Board oversight until scientific, clinical, ethical, and societal concerns are addressed.
For almost a century, the American Society for Reproductive Medicine (ASRM) has been the global leader in multidisciplinary reproductive medicine research, ethical practice, and education. ASRM impacts reproductive care and science worldwide by creating funding opportunities for advancing reproduction research and discovery, by providing evidence-based education and public health information, and by advocating for reproductive health care professionals and the patients they serve. With members in more than 100 countries, the Society is headquartered in Washington, DC, with additional operations in Birmingham, AL. www.asrm.org
For media inquiries regarding this press release contact:
Sean Tipton
ASRM Chief Advocacy and Policy Officer
E: stipton@asrm.org
Anna Hovey
Advocacy Engagement Specialist
E: ahovey@asrm.org
J. Benjamin Younger Office of Public Affairs
726 7th St. SE
Washington, DC 20003
Tel: (202) 863-2494
Press Releases
Check out these press releases as well
ASRM Ethics and Practice Committees Release New Report Concluding Polygenic Embryo Screening Is Not Ready for Clinical Use
New analysis finds that PGT-P lacks proven clinical utility and raises significant scientific and ethical concerns.
ASRM Responds to Speaker Johnson’s Stripping of Fertility Coverage for America’s Military Personnel
ASRM condemns Speaker Johnson’s removal of TRICARE fertility coverage from NDAA, urging action to restore IVF benefits for U.S. military families.
ASRM Center for Policy and Leadership Publishes New Research Analyzing the Trump Administration’s IVF Initiative
ASRM CPL’s new report analyzes the Trump administration’s IVF initiative—examining drug‑pricing, employer fertility benefits, access, equity, and policy implications.
ASRM, Leading Reproductive Health Organizations Attend HHS Policy Convening on Hormone Replacement Therapy (HRT)
HHS and FDA lift black box warning on estrogen therapy. ASRM joins leading orgs in support, urging evidence-based policy for women’s reproductive health.More News from ASRM
Latest News
An indispensable news digest for reproductive scientists, clinicians and allied health professionals.